Joseph Rieman
Child & Adolescent Psychiatry · Fremont, OHNPI 1619138724
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,535 of the $56,236 with a category attached, or 72.1%. Supernus Pharmaceuticals, Inc. accounts for 79.2% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $45,317, more than ten times the $996 reported in 2019. Among child & adolescent psychiatry clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 717 payments — averaging $78.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$45K
- Otsuka America Pharmaceutical, Inc.$2K
- Corium, LLC$2K
- AbbVie$2K
- Alkermes, Inc.$876
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$818
- plus $4K from 19 others
What the payments were for
- Consulting fees$2400%
- Speaking & faculty fees$40,53572%
- Travel & lodging$2,8205%
- Food & beverage$12,48122%
- Education$1600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 112 | $44,548 |
| Otsuka America Pharmaceutical, Inc. | 110 | $2,097 |
| Corium, LLC | 24 | $1,761 |
| AbbVie(2 entities) | 144 | $1,650 |
| Alkermes, Inc. | 51 | $876 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 38 | $818 |
| Ironshore Pharmaceuticals Inc. | 51 | $740 |
| Sunovion Pharmaceuticals Inc. | 38 | $678 |
| Lundbeck LLC | 37 | $661 |
| Teva Pharmaceuticals USA, Inc. | 17 | $426 |
| Johnson & Johnson | 19 | $416 |
| Neurocrine Biosciences, Inc. | 12 | $321 |
| Indivior Inc. | 10 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $151 |
| Axsome Therapeutics, Inc. | 6 | $146 |
| Tris Pharma Inc | 8 | $134 |
| Noven Therapeutics, LLC | 7 | $132 |
| Vanda Pharmaceuticals Inc. | 4 | $113 |
| Avanir Pharmaceuticals, Inc. | 1 | $103 |
| Collegium Pharmaceutical, Inc. | 6 | $94 |
| Shire North American Group Inc | 6 | $75 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $61 |
| Vertical Pharmaceuticals, LLC | 3 | $38 |
| Luye Pharma (USA) Ltd. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$42,624
- Azstarys$1,319
- LYBALVI$833
- ABILIFY MAINTENA$367
- ABILIFY ASIMTUFII$367
- CAPLYTA$124
- LATUDA$120
- REXULTI$118
- INGREZZA$115
- NUEDEXTA$103
How this compares
$56,236 in reported general payments places this provider in the 95th percentile of 160 child & adolescent psychiatry providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 25 | $34,719 |
| CaplytaLumateperone Tosylate | 20 | $31,106 |
| RexultiBrexpiprazole | 14 | $21,488 |
| VyvanseLisdexamfetamine Dimesylate | 47 | $17,912 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,688 |
| Lurasidone Hcl | 12 | $3,361 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 26 | $623 |
| Guanfacine Hcl ErGuanfacine Hcl | 33 | $566 |
| Gabapentin | 37 | $560 |
| Aripiprazole | 17 | $433 |
| Duloxetine Hcl | 31 | $429 |
| Divalproex Sodium ErDivalproex Sodium | 25 | $392 |
| Oxcarbazepine | 16 | $312 |
| Buspirone Hcl | 14 | $236 |
| Clonazepam | 45 | $236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,650 | $34,71925 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $818 | $31,10620 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $151 | $24,60060 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,097 | $21,48814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 160 child & adolescent psychiatry providers in Ohio.
Other child & adolescent psychiatry in Fremont
- Rick BowersMoraine$182K
- Robert FindlingCleveland$125K
- Melissa DelbelloCincinnati$36K
- Andre ProchoroffCleveland$26K
- Peter GoldenAkron$21K
- Daniel WeisMiddletown$13K
- John VraciuCanton$11K
- Debra PankeMansfield$10K
- Barbara GraciousColumbus$10K
- Craig EricksonCincinnati$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.